Press release
US Antidiabetics Drug Market US Antidiabetics Clinical Pipeline Report 2022
Report Table of Contents
Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics
Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication
Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2
Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus
US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills
US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics
US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection
US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch
US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges
US Antidiabetics Drug Market Future Prospects
Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda
Download Report: https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release US Antidiabetics Drug Market US Antidiabetics Clinical Pipeline Report 2022 here
News-ID: 618497 • Views: 261
More Releases from Kuick Resarch
Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024
"Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights:
• Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion
• Trispecific Antibodies In Clinical Trials: > 8 Antibodies
• Highest Phase of Development: Phase I/II
• Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies
• Numab Therapeutics Dominating the Trispecific Development Pipeline
• Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies
Download Report: https://www.kuickresearch.com/report-global-trispecific-antibodies-antibody-market-sales-size-companies-cancer-trispecific--clinical-trials-sar441236--development-conjugate-immunogenicity
Trispecific cancer antibody therapy market at…
Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025
"Global BiTE Antibodies Market, Price, Sales & Clinical Trials Insight 2025" Report Highlights:
• Global BiTE Antibody Market Opportunity Insight (2021-2025)
• Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
• Blincyto Dosage & Market Sales Analysis ( Yearly, Quarterly & Regional Sales)
• Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication & Patient Segment
• Global Bispecific T-Cell Engagers Market Dynamics
Download Report:
https://www.kuickresearch.com/report-global-bite-antibodies-blinatumomab-antibody-immunology-anticancer-market-sales-size-growth-forecast-price-cost-amgen-bispecific-t-cell-engager
The research report, "Global BiTE Antibodies Market , Price, Sales &…
Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 202 …
"Global BCL-2 (B Cell Lymphoma 2) Inhibitors Market & Clinical Trials Insight 2025" Report Highlights:
• Global BCL-2 Inhibitors Market Opportunity: >US$ 4 Billion by 2025
• Insight on Market Indicators & Approved Drugs Sales Data
• Global BCL-2 Inhibitors Market Absolute Growth: >300% ( 97% CAGR, 2018 - 2020)
• Comprehensive Information On Ongoing Clinical Trials
• Global BCL-2 inhibitors Clinical Trials By Company, Indication & Phase
• Venetoclax Is The First Approved Drug Belonging To The Class Of BCL2…
Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research"
"Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights:
• Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs
• Marketed Cancer Antibody Drug Conjugate: 9 Drugs
• Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026
• Majority of Drug Trials Are For Second Line Therapy…
More Releases for Antidiabetic
Global Antidiabetic Biguanides Sales Market Advanced Technologies and Developmen …
Qyresearchreports include new market research report "Global Antidiabetic Biguanides Sales Market Report 2017" to its huge collection of research reports.
This report on the global Antidiabetic Biguanides market has been developed by a selected group of professional market research analysts, with a solitary goal to present the existing scenario of the market for Antidiabetic Biguanides and shed light on its growth prospects. The report targets audiences such as manufacturers of Antidiabetic…
Oral Antidiabetic (OAD) Treatment Market Snapshot by 2017 – 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving toward…
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and…
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment…
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market.
The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into…
Antidiabetic Biosimilars Market, Company Analysis and Forecast to 2024
Antidiabetic biosimilars market overview
Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and…
